Synonym
Flutropium Bromide; Flubron; Ba 598; Ba598; Ba-598
IUPAC/Chemical Name
(1R,3s,5S,8r)-8-(2-fluoroethyl)-3-(2-hydroxy-2,2-diphenylacetoxy)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium bromide
InChi Key
FNUZASGZEHGWQM-BZUXCDCISA-M
InChi Code
InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22-,26+;
SMILES Code
[H][C@]12C[C@@H](OC(C(C3=CC=CC=C3)(C4=CC=CC=C4)O)=O)C[C@](CC1)([N@+]2(CCF)C)[H].[Br-]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
478.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Misawa M, Yanaura S, Hosokawa T, Mizuno H, Irinoda K, Takahashi Y, Yoshimura K, Maruyama Y, Sugimoto K, Ohno H, et al. [Effects of flutropium bromide, a new antiasthma drug, on mediator release from mast cells and actions of mediators]. Nihon Yakurigaku Zasshi. 1988 Feb;91(2):97-103. Japanese. PubMed PMID: 2453423.
2: Mizuno H, Kawabata N, Ohno H, Misawa M. [Effects of flutropium bromide, a new antiasthma drug, with repeated administration on bronchomotor response and hepatic drug metabolizing enzymes]. Nihon Yakurigaku Zasshi. 1989 Jun;93(6):333-40. Japanese. PubMed PMID: 2567689.
3: Bauer R, Fügner A. Pharmacology of the anticholinergic bronchospasmolytic agent flutropium bromide. Arzneimittelforschung. 1986 Sep;36(9):1348-52. PubMed PMID: 2431695.
4: Mizuno H, Takahashi Y, Ohno H, Misawa M. [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. Nihon Yakurigaku Zasshi. 1990 Jan;95(1):31-40. Japanese. PubMed PMID: 1968028.
5: Baba M, Mikami M, Nakamura S, Takizawa J, Kawakami M. [Flutropium bromide was effective in relieving symptoms of lymphangioleiomyomatosis--a case report]. Nihon Kyobu Shikkan Gakkai Zasshi. 1997 Nov;35(11):1223-7. Japanese. PubMed PMID: 9493450.
6: Banholzer R, Pook KH, Stiasni M. Synthesis of the bronchospasmolytic agent flutropium bromide and of some homologous and configuration isomeric compounds. Arzneimittelforschung. 1986 Aug;36(8):1161-6. PubMed PMID: 3778552.
7: Kiel G. Molecular and crystal structure of flutropium bromide. Arzneimittelforschung. 1986 Aug;36(8):1166-8. PubMed PMID: 3778553.
8: Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax. 1995 Jan;50(1):62-6. PubMed PMID: 7886652; PubMed Central PMCID: PMC473711.
9: Namimatsu A, Go K, Tanimoto H, Okuda M. Mechanism of nasal secretion mediated via nerve reflex in guinea pigs and evaluation of antiallergic drugs. Int Arch Allergy Immunol. 1992;97(2):139-45. PubMed PMID: 1374739.
10: Shioya T, Kagaya M, Sano M, Itaba M, Shindo T, Miura M. Antimuscarinic effect of tiquizium bromide in vitro and in vivo. Eur J Clin Pharmacol. 1996;50(5):375-80. PubMed PMID: 8839659.
